

EARLY ACCESS CLINICAL SITE OPPORTUNITY

HerResolve™

Confirming endometriosis presence
with a non-invasive blood test



U.S. CLINICAL SITE QUALIFICATIONS

- Strong desire to bring the first non-invasive, blood-based, diagnostic test to patient who may have endometriosis
- Manages patients aligned with intended use for HerResolve™:
 - Women, ages 18-49
 - Symptomatic for endometriosis (*infertility, pelvic pain, and other symptoms*)
 - Candidate for surgical confirmation and/or resection
 - No definitive diagnosis of endometriosis
- Blood draw, processing and storage capabilities

HerResolve™

The only non-invasive, blood-based test that confirms endometriosis in women experiencing symptoms


Suspicion of endometriosis

- Pelvic pain
- Infertility
- Painful periods
- Dysmenorrhea
- Other

HerResolve blood-based test

- Test Result
 - *Endometriosis Detected or Not Detected*
- Guides personalized treatment and management
 - *Laparoscopic surgery*
 - *Medication*
 - *Reproductive planning*

HerResolve Development Overview and Test Components



HerResolve performance highlights compared to gold standard surgery

	HerResolve ¹	Surgery ²
Sensitivity	90%	90.1%
Specificity	94%	40%
Accuracy	92%	77.1%

1. Interim data on file

2. Gratton, S. et al. "Diagnosis of Endometriosis at Laparoscopy: A Validation Study Comparing Surgeon Visualization with Histologic Findings." *Journal of Obstetrics and Gynaecology Canada*, 2022 Vol 44, Issue 2, 135 - 141.